Schistosomiasis Intensive Treatment With Antimony

Alves, William; Blair, D. M.

doi:10.1016/s0140-6736(46)91181-6

Cited by 28 publications

(5 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Total urinary excretion of antimony over the first 48 h after administration of Sb(V) was 83 ± 6% of the injected amount. The portion of antimony excreted as Sb(III) after administration of Sb(V) was low and variable (1.1–7.6%) over the first 6 h, but rose to 50–56% at 28–48 h, indicating gradual conversion of Sb(V) to Sb(III) in the body. (105) Following intravenous infusion of antimony tartar emetic [KSb(III) tartrate] to eight male African soldiers suffering from schistosomiasis, 21 ± 4% (range 18–23%) of the dose was excreted in urine within 72 h (Alves and Blair, 1946). (106) Bartter et al.…”

Section: Antimony (Z = 51)mentioning

confidence: 99%

See 1 more Smart Citation

ICRP Publication 137: Occupational Intakes of Radionuclides: Part 3

Paquet¹,

Bailey²,

Leggett³

et al. 2017

Ann ICRP

214

View full text Add to dashboard Cite

The 2007 Recommendations of the International Commission on Radiological Protection (ICRP, 2007) introduced changes that affect the calculation of effective dose, and implied a revision of the dose coefficients for internal exposure, published previously in the Publication 30 series (ICRP, 1979, 1980, 1981, 1988) and Publication 68 (ICRP, 1994). In addition, new data are now available that support an update of the radionuclide-specific information given in Publications 54 and 78 (ICRP, 1988a, 1997b) for the design of monitoring programmes and retrospective assessment of occupational internal doses. Provision of new biokinetic models, dose coefficients, monitoring methods, and bioassay data was performed by Committee 2, Task Group 21 on Internal Dosimetry, and Task Group 4 on Dose Calculations. A new series, the Occupational Intakes of Radionuclides (OIR) series, will replace the Publication 30 series and Publications 54, 68, and 78. OIR Part 1 has been issued (ICRP, 2015), and describes the assessment of internal occupational exposure to radionuclides, biokinetic and dosimetric models, methods of individual and workplace monitoring, and general aspects of retrospective dose assessment. OIR Part 2 (ICRP, 2016), this current publication and upcoming publications in the OIR series (Parts 4 and 5) provide data on individual elements and their radioisotopes, including information on chemical forms encountered in the workplace; a list of principal radioisotopes and their physical half-lives and decay modes; the parameter values of the reference biokinetic model; and data on monitoring techniques for the radioisotopes encountered most commonly in workplaces. Reviews of data on inhalation, ingestion, and systemic biokinetics are also provided for most of the elements. Dosimetric data provided in the printed publications of the OIR series include tables of committed effective dose per intake (Sv Bq−1 intake) for inhalation and ingestion, tables of committed effective dose per content (Sv Bq−1 measurement) for inhalation, and graphs of retention and excretion data per Bq intake for inhalation. These data are provided for all absorption types and for the most common isotope(s) of each element. The electronic annex that accompanies the OIR series of publications contains a comprehensive set of committed effective and equivalent dose coefficients, committed effective dose per content functions, and reference bioassay functions. Data are provided for inhalation, ingestion, and direct input to blood. This third publication in the series provides the above data for the following elements: ruthenium (Ru), antimony (Sb), tellurium (Te), iodine (I), caesium (Cs), barium (Ba), iridium (Ir), lead (Pb), bismuth (Bi), polonium (Po), radon (Rn), radium (Ra), thorium (Th), and uranium (U).

show abstract

Section: Antimony (Z = 51)mentioning

confidence: 99%

“…(105) Following intravenous infusion of antimony tartar emetic [KSb(III) tartrate] to eight male African soldiers suffering from schistosomiasis, 21 ± 4% (range 18–23%) of the dose was excreted in urine within 72 h (Alves and Blair, 1946).…”

Section: Antimony (Z = 51)mentioning

confidence: 99%

ICRP Publication 137: Occupational Intakes of Radionuclides: Part 3

Paquet¹,

Bailey²,

Leggett³

et al. 2017

Ann ICRP

214

View full text Add to dashboard Cite

show abstract

“…The next day he showed a close herpetiform rash on the outstanding margin of his R. trapezius muscle, perhaps an affection of the accessory nerve. In this connexion it may be recalled that Alves and Blair (1946) observed a herpetiform rash over the trapezius muscle in one of 100 Africans treated by their intensive course of sodium antimonyl tartrate. Ritchken and Cantor (1947) noted an association between the administration of a similar intensive course of antimony and the onset of herpes zoster in five of their patients.…”

Section: Toxicitymentioning

confidence: 98%

MIRACIL. CLINICAL TRIAL ON PATIENTS INFECTED WITH SCHISTOSOMA HAEMATOBIUM AND S. MANSONI

Blair

Hawking

Meeser

et al. 1949

British Journal of Pharmacology and Chemotherapy

View full text Add to dashboard Cite

A previous paper (Hawking and Ross, 1948) Organization of therapeutic trialThe present investigation was carried out at Salisbury, Southern Rhodesia, beginning in the second half of 1947. Patients with active schistosome infections were selected for the trials. Urines and stools were collected and examined for the presence of eggs and miracidia. The urines were examined by collecting the terminal specimen of urine, centrifuging it, and examining the resultant deposit for eggs. Originally the faeces were examined by collecting material from the outer layers of the stool together with any blood or mucus present and making an emulsion, with pond water, in a 3-in. x 1-in. tube. This emulsion was then filtered through a coffee strainer and transfered to a conical urine glass, further pond water was added, and the whole was allowed to settle. The supernatant was poured off, fresh water was added, and this washing process was repeated several times. Finally the resultant deposit was examined 'microscopically for the presence of eggs. Later, improved methods of diagnosis were used both for urine and faeces, depending on the hatching out of miracidia from the washed deposit and their identification with a hand-lens under indirect illumination (Gorman, Meeser, Ross, and Blair, 1947;Meeser, Ross, and Blair, 1948). Most of the therapeutic trials were made on young patients who were passing eggs in large numbers; infections in adults are less satisfactory for this purpose, since excretion of eggs is often intermittent.Previous to treatment each patient was examined clinically and weighed stripped. The age in Africans can be ascertained only approximately. Before commencing treatment a haemoglobin estimation was

show abstract

“…would resemble that of digitalis. Alves and Blair (1946) have found that in the 72 hours after starting an intensive 2-day course of S.A.T. only 18-28 per cent of the administered dose is excreted in the urine.…”

Section: Effects Of Sodium Antimony Tartratementioning

confidence: 99%

The Effects of Sodium Antimony Tartrate on the Myocardium

Honey¹

1960

Heart

View full text Add to dashboard Cite

Schistosomiasis Intensive Treatment With Antimony

Cited by 28 publications

References 3 publications

ICRP Publication 137: Occupational Intakes of Radionuclides: Part 3

ICRP Publication 137: Occupational Intakes of Radionuclides: Part 3

MIRACIL. CLINICAL TRIAL ON PATIENTS INFECTED WITH SCHISTOSOMA HAEMATOBIUM AND S. MANSONI

The Effects of Sodium Antimony Tartrate on the Myocardium

Contact Info

Product

Resources

About